Search Results for: stem cell therapy

Cord blood for cerebral palsy: mostly discouraging new trial data

/ / 6 Comments
umbilical-cord-blood, umbilical cord blood stem cells

Some notable newly published Phase II data from the Duke cord blood for cerebral palsy trial unfortunately doesn’t give much reason for optimism that this approach is going to have a substantial positive effect for these kids. The double-blinded, placebo-controlled study did not find a meaningful benefit overall from infusions of autologous cord blood (ACB) for […]

Cord blood for cerebral palsy: mostly discouraging new trial data Read More »

Countering that Pro-Heritable Human CRISPR WSJ Piece

/ / 9 Comments
human-embryo-modification

It’s germline, heritable human CRISPR time, right? Wrong. But the particularly enthusiastic supporters of heritable human CRISPR often cite hypothetical benefits in glowing terms, but either don’t mention risks or strongly downplay them. These fans also tend to leave alternative, proven and safe technologies such as preimplantation genetic diagnosis (PGD) out of the discussion or

Countering that Pro-Heritable Human CRISPR WSJ Piece Read More »

Senate Passes Federal Right-To-Try: Poll on Your Opinion

/ / 4 Comments
Right-To-Try

The U.S. Senate just passed a bill that if it becomes law would codify Right-To-Try as a federal law, meaning terminally patients across the U.S. could ask their physicians and drug manufacturers to be given still investigational therapies such as still unproven stem cell therapies in development. The bill’s official name is “The Trickett Wendler

Senate Passes Federal Right-To-Try: Poll on Your Opinion Read More »

Reading the tea leaves as new FDA commish Gottlieb blogs on regenerative medicine

/ / 3 Comments
Dr.-Scott-Gottlieb

New FDA Commissioner Dr. Scott Gottlieb, M.D., has in the past touched on stem cells and regenerative medicine therapies in speeches or written comments prior to starting his tenure at the agency. Now that he is Commissioner, he is poised to have direct impact on our field rather quickly and potentially with major changes in

Reading the tea leaves as new FDA commish Gottlieb blogs on regenerative medicine Read More »

Highlights of ISSCR2017 – A Biomedical Engineer’s Perspective

/
Agnes-Soos

ISSCR meeting review By Agnes Soos Amid the hustle and bustle of downtown Boston, nearly four thousand researchers and exhibitors gathered for the 15th Annual ISSCR Meeting. With presentations from over thirty plenary lectures, and dozens of others featured in concurrent sessions and the daily Innovation Showcases, there definitely was no shortage of exciting research

Highlights of ISSCR2017 – A Biomedical Engineer’s Perspective Read More »

Dr. Jeffrey Weiss, SCOTS trial, & Patient Claims of Blindness

/ / 6 Comments
Eye-injection-e1478306814439

Two physicians are central to something called the SCOTS trial, Dr. Jeffrey Weiss and Steven Levy. Patients have claimed negative outcomes after participating in the trial. What’s going on here? SCOTS trial The recent NEJM paper reporting on the blinding of three patients in Florida may be just the beginning. More information has come out on negative

Dr. Jeffrey Weiss, SCOTS trial, & Patient Claims of Blindness Read More »

Quick journal club on IPSC anti-aging paper: cool, but outstanding questions

/ / 6 Comments
IPSC-anti-aging-paper

A new Cell paper from Juan Carlos Izpisua Berlmonte’s group has made headlines about anti-aging across the globe because it suggests that the four core induced pluripotent stem cell (IPSC) factors use by Shinya Yamanaka to make IPSC can reverse aging. I’ve pasted the graphical abstract from the paper below and done a quick journal club style

Quick journal club on IPSC anti-aging paper: cool, but outstanding questions Read More »

Chat with Michael Werner of ARM on Cures Act regenerative medicine provisions

/
Michael-Werner-Pic

One of the hottest topics in the world of stem cells this year has been the REGROW ACT and at a larger level the movement for changes in FDA oversight of investigational regenerative medicine therapies (see my past posts on it here), so the related provisions in the 21st Century Cures Act are stirring much

Chat with Michael Werner of ARM on Cures Act regenerative medicine provisions Read More »

Cynata approval for 1st ever allo trial of IPSC-derived MSCs for GVHD

/ / 6 Comments
Cynata

Cynata Therapeutics Limited has received approval from UK regulators to start a first-of-its-kind allogeneic IPSC-based trial of MSCs for graft versus host disease (GVHD). Cynata also had some big news a couple weeks back with a deal with Fujifilm. The company is aiming to recruit 16 patients to test whether the MSCs (a type of adult

Cynata approval for 1st ever allo trial of IPSC-derived MSCs for GVHD Read More »